A Glimpse of ASH
Dr Isabel Cunningham discusses some of the important studies presented at the 2016 ASH meeting.
Dr Isabel Cunningham discusses some of the important studies presented at the 2016 ASH meeting.
Daratumumab plus lenalidomide and dexamethasone (DRd) is superior to lenalidomide plus dexamethasone (Rd).
Daratumumab plus bortezomib and dexamethasone (DVd) is superior to bortezomib plus dexamethasone (Vd).
Idarubicin plus high-dose cytarabine (HDAC) with or without vorinostat was not superior to 7+3 chemotherapy.
Some patients with chronic myeloid leukemia (CML) who have maintained deep molecular responses for at least 2 years can safely discontinue nilotinib.
Tyrosine kinase inhibitor (TKI) cessation appears feasible and safe in patients with chronic myeloid leukemia in chronic phase (CML-CP).
There were no differences in molecular relapse-free survival between patients with prior 4.5 log reduction but detectable disease and those with undetectable disease
Tyrosine kinase inhibitors (TKIs) can be safely and successfully discontinued a second time despite failing first discontinuation.
All-trans retinoic acid (ATRA) plus arsenic trioxide with or without chemotherapy induces high remission rates.
Generic formulations of imatinib appear to be non-inferior to Novartis’s Gleevec brand formulation with respect to clinical efficacy and tolerability.